Discover the key elements of President Trump's new trade deal with the EU, including significant changes to tariffs on cars, pharmaceuticals, and more. Find out how this will affect trade relations and investments!
The White House unveils a $550 billion investment agreement with Japan, promising strategic investments in key sectors. But experts raise doubts about its feasibility amidst ongoing tariff controversies.
As Trump meets EU leaders in Scotland, intense negotiations are underway to prevent a costly trade war. With key issues at stake and heavy security, will a new trade deal emerge?
Isomorphic Labs, leveraging AI breakthroughs from DeepMind, is on the brink of human clinical trials for cancer drugs. With major pharma partnerships, the future of drug design looks promising!
In a surprising turn, Anne Wojcicki's nonprofit, TTAM Research Institute, has acquired 23andMe for $305 million after its bankruptcy. This acquisition addresses concerns about genetic data privacy while aiming to uphold the company's mission.
Anne Wojcicki's nonprofit has won the bid to buy 23andMe, raising critical questions about the future of genetic data privacy. Experts warn that sensitive DNA information could be at risk.
In a groundbreaking move, 27 states and D.C. have filed a lawsuit to prevent 23andMe from selling customer genetic data without consent. This legal battle raises significant privacy concerns for users.
Hims & Hers Health is set to acquire European telehealth platform Zava, aiming to expand its services across Europe. The deal promises to add 1.3 million customers and enhance access to affordable medications in Ireland, France, and Germany.
In a surprising move, Lars Fruergaard Jørgensen is stepping down as CEO of Novo Nordisk after years of leading the company through a successful phase in obesity and diabetes medications. As the search for his successor begins, what does this mean for the future of the pharmaceutical giant?
Pharma faces a daunting challenge as Trump takes bold steps to cut drug prices. With RFK Jr. praising the move, is bipartisanship on the horizon or will the industry fight back?
